OriCell Therapeutics Announces $110 Million Pre-IPO Round, Co-Led by Qiming Venture Partners
Global leader in innovative tumor immunotherapy
Qiming Venture Partners portfolio company OriCell Therapeutics, a global leader in innovative tumor immunotherapy, has officially announced the completion of a cumulative $110 million Pre-IPO financing round. The proceeds will primarily accelerate OriCell's international strategic expansion, advance the global multi-center clinical development of its core pipeline, further solidify its technological moat in cell therapy, and expedite the value realization of its commercialization pipeline — all in preparation for its upcoming capital markets milestone.
As a leading enterprise in cell therapy drugs, OriCell Therapeutics has remained dedicated to developing CAR-T cell therapies with global clinical value, having achieved confirmatory proof-of-concept (POC) clinical data across multiple pipeline programs. Leveraging its proprietary Ori®Ab antibody screening and engineering platform, Ori®Armoring structural enhancement platform, and OnGo(Fast) CMC rapid process expertise, OriCell has successfully built a differentiated product portfolio, securing a leading position in the global CAR-T technology race.
OriCell's flagship product is Ori-C101, an autologous CAR-T drug targeting GPC3 for the treatment of advanced hepatocellular carcinoma (HCC). The product has completed investigator-initiated trials (IIT) and registrational Phase I clinical trials, with pivotal clinical trials imminent. Clinical data readouts to date have demonstrated excellent efficacy and safety profiles, with findings presented multiple times at ASCO (American Society of Clinical Oncology Annual Meeting) and other top-tier international academic conferences. Given its positive clinical progress, Ori-C101 is positioned to potentially become the world's first approved CAR-T drug for hepatocellular carcinoma.
Beyond its core pipeline, OriCell's full-platform technology system continues to incubate multiple next-generation multi-target, multi-mechanism CAR-T products, including secretory, rapid-manufacturing, and several in vivo CAR-T programs.
Dr. Huanfeng Yang, Chairman and CEO of OriCell Therapeutics, stated: "We are deeply grateful to our investors for their strong recognition of our vision and technological capabilities. This financing round represents a significant milestone in OriCell's development journey. We will continue to focus on global clinical advancement of our core pipeline, deepen R&D in revolutionary technologies such as in vivo CAR-T and solid tumor CAR-T, and fully capitalize on our multiple advantages in technical accumulation, policy environment, and market demand to accelerate development speed, reduce costs, and improve accessibility for our clinical-stage products. Our goal is to bring new curative hope to cancer patients worldwide with more breakthrough cell therapy solutions, and steadily advance toward becoming a global leader in immunotherapy."
William Hu, Managing Partner of Qiming Venture Partners, commented: "As an early investor that has accompanied OriCell since its Pre-A round, we have witnessed every step of the company's journey — from technology exploration to pipeline execution and clinical progress, from local innovation to global expansion. We look forward to OriCell achieving next-generation cancer treatment through breakthrough cell therapy solutions and superior clinical data, delivering curative hope to patients worldwide."
This financing round was co-led by Vivo Capital, Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading healthcare fund, with follow-on investments from a prominent international sovereign fund, Beijing E-Town International Investment & Development Co., Ltd., Luxin Venture Capital Group Co.,Ltd., NGS (Australia's pension industry fund), Lichen Capital, Ruifeng Capital, and other notable institutions.
Past Coverage
Qiming Perspectives | William Hu: Chinese Innovation Is Moving From Scattered Breakthroughs to Large-Scale Comprehensive Advances Qiming Stars | OriCell Therapeutics Completes First Closing of $70 Million Series C Financing, Accelerating Global Development of Solid Tumor CAR-T Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol. 12, 2026.4.7
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their respective industries.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.